Get the Stockscreener App
27.39
8.91%
2.24
After Hours:
28.10
0.71
+2.59%
Upstream Bio Inc stock is traded at $27.39, with a volume of 544.65K.
It is up +8.91% in the last 24 hours and up +0.00% over the past month.
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases.
See More
Previous Close:
$25.15
Open:
$26
24h Volume:
544.65K
Relative Volume:
6.00
Market Cap:
$1.47B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+8.86%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$25.50
$28.98
1-Week Range:
$24.35
$28.98
52-Week Range:
$20.74
$28.98
Upstream Bio Inc Stock (UPB) Company Profile
Upstream Bio Inc Stock (UPB) Latest News
Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say - Benzinga
This Eaton Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Upstream Bio (NASDAQ:UPB) Earns Overweight Rating from Analysts at Piper Sandler - MarketBeat
TD Cowen bullish on Upstream Bio, bets on differentiated asthma treatment verekitug - Investing.com
Upstream Bio prices IPO at $17 per share - MSN
Finance Watch: Septerna Raises $288m In Public Market Debut - Citeline
Septerna Shares Jump 19% After IPO Shows Biotech Still Hot - Bloomberg
CeriBell Shares Rise 47% to Lead Trio of Life Sciences IPOs - MSN
Goldman-backed drug developer Septerna raises $288 mln in US IPO - Reuters
Upstream Bio stock rallies 32% following upsized $255M IPO - MSN
Upstream Bioprocessing Market Forecast 2024: Key Global Developments - openPR
Upstream Bio Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Upstream Bio Rings the Opening Bell - Nasdaq
Warren Buffett and Biotech IPOs Highlight Recent Insider Buying - 24/7 Wall St.
Insider Trading Recap: Thursday's Top Buys and Sells in US Stocks - Investing.com
Orbimed Advisors LLC Acquires New Stake in Upstream Bio Inc - Yahoo Finance
Upstream bio director Erez Chimovits buys $14 million in shares By Investing.com - Investing.com South Africa
Upstream bio director Erez Chimovits buys $14 million in shares - Investing.com
OrbiMed Advisors LLC purchases $14 million in Upstream Bio shares - Investing.com
Some of the Major Key Players in the Continuous Bioprocessing Market are - InsightAce Analytic
Upstream Bio Announces Closing of $293 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares - The Manila Times
Chronic Rhinosinusitis with Nasal Polyps Market Expected - openPR
Upstream Bio and Camp4 and Ceribell Transactions - William Blair
UPB News Today | Why did Upstream Bio stock go down today? - MarketBeat
Upstream Bio shares soar in impressive IPO - The Pharma Letter
Opening Day: Another trio of biotech IPOs make Friday debut - Yahoo Finance
HBM portfolio company Upstream Bio raises USD 255 million in successful initial public offering - Marketscreener.com
Upstream Bio Leads Life Sciences IPOs With Upsized Listing - MSN
Upstream catches aftermarket updraft, as Camp4 IPO gets muted reception - BioCentury
Finance Watch: 2024 Has Now Beaten 2023’s Total Of 21 IPOs - Scrip
Aiming to Outdo Rivals in Severe Asthma, Upstream Bio Upsizes IPO to $225M - MedCity News
Upstream Bio Shares Rise 26% to Lead Burst of Life Sciences IPOs - MSN
6 Firms Guide IPO Trio From Biotech, Medical Device Cos. - Law360
Upstream Bio Shares Jump on First Day of Trading - MarketWatch
Shares of one Mass. biotech rises, another one mostly flat, after IPOs - The Business Journals
Upstream Bio stock rallies 32% following upsized $255M IPO (NASDAQ:UPB) - Seeking Alpha
Upstream Bio valued at $1.1 billion as shares jump in Nasdaq debut - WTVB
Upstream Bio Opens At $21.50, IPO Priced At $17 By Investing.com - Investing.com Canada
Upstream Bio valued at $1.1 bln in stellar debut as healthcare IPOs heat up - TradingView
Upstream Bio, two other U.S. biotech startups price IPOs as healthcare listings rise - Reuters
Upstream Bio Prices Upsized 15M Share IPO at $17/sh - Investing.com
Upstream Bio Leads Three Life Sciences IPOs With Upsized Listing - MSN
Upstream Bio raises $255 million in US IPO - MSN
Two more Mass. biotechs raise $330M in IPOs, to debut on Nasdaq - The Business Journals
Upstream Bio Announces Pricing of Upsized Initial Public Offering - ForexTV.com
Upstream Bio Announces Pricing Of Upsized Initial Public Offering - XM
Preview: Upstream Bio, Inc Set To IPO Tomorrow - Benzinga
Upstream Bio Inc Stock (UPB) Financials Data
There is no financial data for Upstream Bio Inc (UPB). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Upstream Bio Inc Stock (UPB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | Director |
Oct 15 '24 |
Buy |
17.00 |
825,000 |
14,025,000 |
4,554,873 |
| AI Upstream LLC | 10% Owner |
Oct 15 '24 |
Buy |
17.00 |
1,175,000 |
19,975,000 |
1,175,000 |
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):